论文部分内容阅读
目的探讨舒利迭单用与合用白三烯拮抗剂孟鲁司特(MON)对老年支气管哮喘(BA)的临床效果。方法选择2014年3月至2015年2月老年支气管哮喘患者120例,按照治疗方案分为两组,联合组60例给予口服孟鲁司特与吸入舒利迭治疗,而舒利迭组60例仅给予吸入舒利迭治疗。观察两组患者一秒用力呼气容积(FEV1)、用力肺活量(FVC)和最大呼气流速(PEF),比较两组患者的咳嗽、哮喘和胸闷症状缓解时间,评价其综合疗效。结果治疗后联合组FEV1、FVC和PEF分别为(1.32±0.39)L、(2.13±0.62)L和(3.15±1.32)L,舒利迭组为(1.15±0.26)L、(2.01±0.51)L)L和(2.80±1.01)L,联合组咳嗽、哮喘和胸闷症状缓解时间明显短于舒利迭组;联合组总有效率为93.3%,舒利迭组为73.3%;两组比较差异均统计学意义(P<0.05)。结论舒利迭结合孟鲁司能明显改善老年支气管哮喘患者的肺功能,迅速缓解患者临床症状,疗效显著,值得临床推广应用。
Objective To investigate the clinical efficacy of seretide alone and in combination with montelukast (MON) on senile bronchial asthma (BA). Methods A total of 120 elderly patients with bronchial asthma were selected from March 2014 to February 2015. The patients were divided into two groups according to the treatment regimen. Sixty patients in combination group were treated with montelukast and inhaled seretide, and 60 patients with seretide Only given inhaled Seretide treatment. The forced expiratory volume (FEV1), forced vital capacity (FVC) and maximum expiratory flow rate (PEF) of the two groups were compared between the two groups to compare the cough, asthma and chest pain relief time of two groups to evaluate the comprehensive effect. Results After treatment, FEV1, FVC and PEF in the combined group were (1.32 ± 0.39) L and (2.13 ± 0.62) L and (3.15 ± 1.32) L, respectively, and were 1.15 ± 0.26 and 2.01 ± 0.51 L and (2.80 ± 1.01) L, the time of relieving cough, asthma and chest tightness in the combined group was significantly shorter than that in the seretide group. The combined effective rate was 93.3% in the combined group and 73.3% in the seretide group. The difference between the two groups was significant All statistically significant (P <0.05). Conclusion Seretide combined with montelukast can significantly improve the lung function of elderly patients with bronchial asthma and quickly alleviate the clinical symptoms of patients with significant curative effect, worthy of clinical application.